Guideline Tumour Markets 4th

Guidelines for the use
of tumour markers
ACBI
Scientific
Committee
Guidelines
The Association Of Biochemists in Ireland - Guidelines for the use of tumour markers The Association Of Biochemists in Ireland - Guidelines for the use of tumour markers
Guidelines for the use of

tumour markers
Association of Clinical Biochemists in Ireland
MJ Duffy P McGing
Fourth edition: October 2010 Fourth edition: October 2010

The Association Of Biochemists in Ireland - Guidelines for the use of tumour markers
Contents
Produced by the
Scientific Committee Preface vii
of the
Association of Clinical Biochemists in Ireland Introduction 1
(ACBI)
General References on Tumour Markers 3
Alpha-Fetoprotein (AFP) 4
Fourth edition: October 2010
CA 125 6
ISSN 2009-3977
CA 15-3 8
CA 19-9 10
CEA 12
Human Chorionic Gonadotropin (hCG) 14
Prostate Specific Antigen (PSA) 16
Free PSA (fPSA) 20
Use of Serum Markers in Diagnosing Cancer of

Other booklets in this series Unknown Primary Origin (Occult Cancers) 23
Guidelines on the use of biochemical cardiac markers and risk factors
Guidelines on the use of therapeutic drug monitoring Tissue Markers in Breast Cancer 24
The biochemistry of body fluids Estrogen and Progesterone Receptors (ER and PR) 24
HER-2 (c-ErbB-2) 25
Urokinase Plasminogen Activator (uPA) and PAI-1 26
v
Preface
This is the 4th edition of the well established publication ‘Guidelines for the
use of Tumour Markers’ and is part of a series commissioned and produced
by the Scientific Committee of the Association of Clinical Biochemists in
Ireland to promote appropriate and effective use of the laboratory service. It
is intended to be a concise reference document to assist both practitioners
in the Clinical Biochemistry field and those who are users of the laboratory
service.
The guidelines in this new edition are based upon up to date scientific
evidence and expert consensus and will provide support for consistency
of test requesting. There is also a new section outlining the use of Tumour
Markers in patients with a cancer of unknown primary origin and it is hoped
that this section will provide useful guidance in what is considered a difficult
clinical management situation.
On behalf of ACBI Council, I would like to express our gratitude to the
Scientific Committee and the individual authors for their work on this
project. In particular, we are honoured to have Prof Joe Duffy as the lead
author. Prof Duffy has published extensively in this field and has been a lead
contributor to major international guidelines for the use of Tumour Markers.
Council is also grateful to Cruinn Diagnostics Ltd and Siemens Ltd for their
generous financial contribution to the printing costs of this new edition.
Ms Orla Maguire,
President, ACBI
October 2010
vi Guidelines for the use of tumour markers vii

Introduction
The purpose of this booklet is to give a brief background to enable the
judicious use of seven widely performed serum cancer markers. The format
used here is similar to that in previous editions. However, in this 4th edition,
we provide for the first time, a section on the use of serum markers in the
diagnosis of tumours of unknown primary origin
While this booklet gives specific details relating to the most frequently used
markers, we feel that it is important to make some general points about
tumour marker tests.
• No serum marker in current use is specific for malignancy.
• Generally, serum marker levels are rarely elevated in patients with
early malignancy. With a few exceptions, high levels are usually found
only when patients have advanced disease.
• No cancer marker has absolute organ specificity. PSA however,
appears to be relatively specific for prostate tissue, but not for prostate
cancer.
• Apart from possibly hCG in choriocarcinoma, no marker is elevated
in 100% of patients with a particular malignancy.
• Requesting of multiple markers (such as CEA and the CA series of
antigens) in an attempt to identify metastases of unknown primary
origin is rarely of use (see below).
• Tumour markers assays should not be carried out on biological fluids
such as peritoneal fluids, pancreatic juice and ovarian cystic fluids as
reliable reference ranges are currently unavailable for these types of
specimen.
• Reference ranges for cancer markers are not well defined and are used
only for guidance. Please note that a level below the reference range
does not exclude malignancy while concentrations above the reference
range does not necessary mean the presence of cancer. Changes in
levels over time are likely to be more clinically useful than absolute
levels at one point in time.
• As many tumour markers lack agreed International Reference
Preparations (e.g CA125, CA15-3, CA19-9), different assay kits may
give different results for the same sera.
• Laboratories carrying out tumour marker tests should state the assay
used on their report form.
viii Guidelines for the use of tumour markers 1

General References on Tumour
Markers
1. Duffy MJ. Clinical uses of tumor markers: a critical review.
Crit Rev Clin Lab Sci 2001;38:225-262.
2. Duffy MJ. Role of tumor markers in patients with solid tumors: a
critical review.
Eur J Int Med 2007;18:175-184.
3. Sturgeon CM, Lai LC, Duffy MJ. Serum tumor markers: how to order
and interpret them.
Br Med J 2009;339:852-858.
4. Sturgeon CM, Duffy MJ, Stenman U, et al. National Academy of
Clinical Biochemistry Laboratory Medicine Practice Guidelines for
Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and
Ovarian Cancers.
Clin Chem 2008;54:e11-e79.
5. Sturgeon C, Duffy MJ, Hoffman, et al. National Academy of Clinical
Biochemistry Laboratory Medicine Practice Guidelines for Use of
Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers.
Clin Chem 2010;56:e1-e48.
2 Guidelines for the use of tumour markers 3

Alpha-Fetoprotein (AFP)
Structure recommended using 6-monthly AFP measurement and abdominal
AFP is a 70 kDa glycoprotein homologous to albumin. ultrasound, with AFP>20 µg/L and rising prompting further
investigation.
Forms in serum
AFP exhibits microheterogeneity probably due to varying levels of e. Note that AFP is not a useful marker for liver metastases. For liver
glycosylation. AFP produced by malignancies appears to be more highly metastases, CEA is preferable marker.
fucosylated than that formed by normal tissues. Reference range
0 - 10 kU/L or 0-12 mg/L
Physiological function
Appears to perform some of the functions of albumin in the foetal Half life in serum
circulation. Approx. 5 days.
Malignancies with elevated levels Comment on assay
Mainly confined to 3 malignancies, i.e. Existing immunoassays appear to detect total AFP and do not discriminate
a. Non-seminomatous germ cell tumours (NSGCT) of testis, ovary and between different glycosylated forms.
other sites.
b. Hepatocellular carcinoma (HCC).
References
c. Hepatoblastoma (in children, extremely rare in adults). 1. International Germ Cell Cancer Collaborative Group. International
d. AFP may be occasionally elevated in patients with other types of germ cell consensus classification: a prognostic factor-based staging
advanced adenocarcinoma. system for metastatic germ cell cancers.
Benign conditions which may have elevated levels J Clin Oncol 1997;15:594-603.
Hepatitis, cirrhosis, biliary tract obstruction, alcoholic liver disease, ataxia 2. Bruix J, Sherman M. Management of hepatocellular carcinoma.
telangiectasia and hereditary tyrosinaemia. Hepatology 2005;42:1208-36.
3. Sturgeon C, Duffy MJ, Hoffman, et al.
Physiological conditions with elevated levels
National Academy of Clinical Biochemistry Laboratory Medicine
Pregnancy and the first year of life. Infants have extremely high levels which
Practice Guidelines for Use of Tumor Markers in Liver, Bladder,
fall to adult values between 6 months and 1 year of age. A slower than
Cervical, and Gastric Cancers.
normal rate of fall may indicate the presence of a tumour.
Clin Chem 2010;56:e1-e48.
Main clinical applications
a. In combination with hCG, for monitoring patients with NSGCT
(mandatory).
b. Independent prognostic marker for NSGCT (e.g. of the testis).
c. Diagnostic aid for hepatocellular carcinoma and hepatoblastoma.
In patients with cirrhosis and a focal lesion > 2 cm with arterial
hypervascularization, an AFP level >200 µg/L is suggestive of HCC, and
AFP>400 µg/L is strongly suggestive of HCC.
d. Screening for hepatocellular carcinoma in high risk populations (e.g.
in patients with cirrhosis due to hepatitis B or C). Surveillance is
4 Guidelines for the use of tumour markers Alpha-Fetoprotein (AFP) 5

CA 125
Structure Type of sample for assay
CA 125 refers to the antigen originally detected by the OC-125 antibody. Serum is recommended.
The protein detected by this antibody is Muc16, a mucin with a single CA 125 may be assayed on other fluid samples (e.g. ascitic fluid) but this
transmembrane domain. cannot be recommended (outside of research projects), on analytical and
Forms in serum interpretational grounds.
The major forms in serum have molecular weights of 200 kDa to 400 kDa. Reference range
0 - 35 kU/L (most frequently used range).
None established. Please note however, that levels may be higher in premenopausal than
postmenopausal women.
Malignancies with elevated levels
a. Epithelial ovarian cancer; 80 - 85% of all cases; but increased in only half Half life in serum
of early (stage 1) cancer. Approx. 5-7 days.
b. May be elevated in any adenocarcinoma with advanced disease.
Benign conditions which may have elevated levels References
Endometriosis, acute pancreatitis, cirrhosis, peritonitis, inflammatory pelvic 1. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA 125 in ovarian cancer:
disease. The presence of ascites (of non-malignant origin) can also give rise European Group on Tumor Markers (EGTM) guidelines for clinical
to elevated serum levels of CA 125. use.
Int J Gynecol Oncol 2005;15:679
Menstruation and pregnancy may be associated with moderately elevated 2. Tuxen MK, Soletormos G, Dombernowsky P. Serum tumour
serum CA 125 (usually not more than 100 kU/L) marker CA 125 in monitoring of ovarian cancer during first-line
chemotherapy.
Main clinical applications Br J Cancer 2001;84:1301-1307.
a. While CA125 should not be used in screening asymptomatic women for
sporadic ovarian cancer, its measurement in postmenopausal patients
with pelvic masses may help differentiate malignant from benign
lesions.
b. The rate of decline during initial therapy is an independent prognostic
indicator in ovarian carcinoma.
c. Monitoring treatment with chemotherapy.
d. Surveillance following initial treatment. The impact of this on survival is
unclear.
6 Guidelines for the use of tumour markers CA 125 7

CA 15-3
Structure References
CA 15-3 is a transmembrane glycoprotein encoded by the MUC1 gene. It is 1. Duffy MJ. CA 15-3 and related mucins as markers in breast cancer: a
defined by reactivity with 2 monoclonal antibodies, i.e., DF3 and 115D8 in a critical review.
sandwich immunoassay. Ann Clin Biochem 1999;36:579-586.
Physiological function 2. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical
May be involved in cell adhesion and cancer pathogenesis. value?
Clin Chem 2006;52:345-51.
3. Molina R, Barak V, van DA, Duffy MJ, Einarsson R, Gion M, et al.
Breast and other adenocarcinomas, especially with distant metastasis. Rarely
Tumor markers in breast cancer - European Group on Tumor Markers
elevated in patients with local breast cancer.
recommendations. Tumour Biol 2005;26:281-93.
Benign diseases with elevated levels 4. Harris L, Fritsche H, Menel R, Norton L, Ravidin P, Taube S, et al.
Benign liver disease, possibly benign breast disease. American Society of Clinical Oncology 2007 Update of
recommendations for the use of tumor markers in breast cancer. J
Main clinical applications: Clin Oncol 2007;25:5287-312.
a. For preclinically detecting recurrences in asymptomatic patients with
diagnosed breast cancer. Use of CA 15-3 in this setting is controversial.
b. For monitoring the treatment of patients with advanced breast cancer,
especially in patients with disease that cannot be evaluated using
standard criteria.
Reference range
0 – 25 to 0 – 40 kU/L
Half life in serum
Unknown
Comment about assay
Other assays such as BR 27.29 appear to measure the same antigen as
CA 15-3
8 Guidelines for the use of tumour markers CA 15-3 9

CA 19-9
A mucin which reacts with monoclonal antibody 111 6 NS 19-9. 1. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers.
Physiological function 1. Ann
May be involved in cell adhesion. Clin Biochem 1998;35:364-370.
2. Duffy MJ, Sturgeon C, Lamerz R, et al, Tumor Markers in Pancreatic
Malignancies with elevated levels Cancer: A European Group on Tumor Markers (EGTM) Status
Most pancreatic adenocarcinomas, approx. 50% of gastric carcinomas and Report.
approx. 30% of colorectal carcinomas. Ann Oncol 2010;21:441-447.
Benign conditions which may have elevated levels
Acute and chronic pancreatitis, hepatocellular jaundice, cirrhosis, acute
cholangitis and cystic fibrosis.
a. As a diagnostic aid for pancreatic carcinoma. Inadequate sensitivity and
specificity limit the use of CA 19-9 in the early diagnosis of pancreatic
cancer. However, in non-jaundiced patients, CA 19-9 may complement
other diagnostic procedures.
b. Monitoring treatment of patients with pancreatic adenocarcinoma.
Other potential uses
Diagnostic aid in gastric and cholangio carcinomas. For colorectal cancer,
CEA is generally more valuable than CA 19-9.
Reference range
Very variable, from 0 - 37 kU/L to 0 - 100 kU/L
Half life in serum
Approx. 1 day but can vary from less than 1 day to 3 days.
10 Guidelines for the use of tumour markers CA 19-9 11

CEA
A 200 kDa (approx.) glycoprotein. 1. Duffy MJ. CEA as a marker for colorectal cancer: is it clinically useful.
Clin Chem 2001;47:624-630.
Appears to play a role in cell adhesion and inhibition of apoptosis. 2. Duffy MJ, van Dalen A, Haglund C. Clinical utility of biochemical
markers in colorectal cancer: European Group on Tumor Markers
Malignancies with elevated levels (EGTM) guidelines.
Can be elevated in almost any advanced adenocarcinoma, i.e., where distant Eur J Cancer 2003;39:718-727.
metastases are present. Almost never elevated in early malignancy. 3. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of
Benign diseases which may have elevated levels recommendations for the use of tumor markers in gastrointestinal
Hepatitis, cirrhosis, alcoholic liver disease, obstructive jaundice, ulcerative cancer.
colitis, Crohn’s disease, pancreatitis, bronchitis, emphysema and renal J Clin Oncol 2006;24:5313-27.
disease. Levels may also be mildly elevated in apparently healthy individuals 4. Duffy MJ, van Dalen A, Haglund C, Hansson, et al. Tumour markers
who smoke. in colorectal cancer: European Group on Tumour Markers (EGTM)
guidelines for clinical use.
Physiological conditions with elevated levels Eur J Cancer 2007;43:1348-1360.
None to our knowledge.
a. In surveillance following curative resection of colorectal cancer.
b. In monitoring therapy in advanced colorectal cancer. This is especially
important when disease cannot be evaluated by standard criteria.
May also be useful in other gastrointestinal malignancies and as a “general
purpose” marker for adenocarcinomas. Please note however, that CEA is
rarely elevated in patients with any type of local cancer.
Reference range
0 - 3.5 µg/L to 0 - 5.0 µg/L.
Half life in serum
Approx. 3 days but can vary from 1 to 5 days.
12 Guidelines for the use of tumour markers CEA 13

Human Chorionic Gonadotropin (hCG)
Structure Type of sample for assay
hCG is a heterodimer composed of 2 glycosolated sub-units (alpha and Serum or urine.
beta chains) non-covalently bonded. The alpha chain is almost identical to
the alpha chain in TSH, FSH and LH. The beta chain is distinct from the Reference range
corresponding chains in TSH and FSH but has a high degree of homology Serum: 0 - 5 IU/L.
with LH over the first 75% of the amino sequence. hCG however, possesses a Half life in serum
distinctive 24 amino acid carboxy-terminal extension. Approx. 16 - 24 hours; decline may be biphasic with a second half life of 13
Forms in serum days.
hCG can exist in multiple forms including the intact 2-chain peptide, free Comment about assay
alpha and beta chains, as well as various degradation products (e.g., beta When used as a tumour marker, assays for hCG should detect all the main
core fragment). forms, especially the intact molecule and beta-subunit.
Physiological function Some hCG assays may give either false-positive or false-negative results. If
To maintain progesterone production by the corpus luteum during early false-positive results are suspected, then measure hCG in urine.
pregnancy. hCG can be detected as early as one week after conception. Note: some methods for hCG may cross-react with LH.
a. Virtually all patients with gestational trophoblastic disease (GTD)
References
(i.e., complete and partial molar pregnancy, choriocarcinoma and
1. Sturgeon C and McAllister EJ. Analysis of hCG. Clinical applications
placental site trophoblastic tumours).
and assay requirements.
b. Non-seminomatous germ cell tumours (NSGCT) (e.g., of testis and Ann Clin Biochem 1998;35:460-491.
ovary).
2. Stenman U-H et al. Human chorionic gonadotropin in cancer.
c. Seminomatous germ cell tumours of testis (approx. 20%). Clinical Biochem 2004;37:549-561
d. Can be produced by a small number of other malignancies. 3. Cole LA. Human chorionic gonadotropin and associated molecules.
Benign Diseases With elevated levels Expert Rev Mol Diagn 2009;9:51-73.
Very few, e.g., ectopic pregnancy, pituitary adenoma. 4. Sturgeon CM, Berger P, et al on behalf of the IFCC Working Group
on hCG. Differences in recognition of the 1st WHO international
reference reagents for hCG-related isoforms by diagnostic
Pregnancy, after termination of pregnancy.
immunoassays for human Chorionic Gonadotropin.
Main clinical applications Clin Chem 2009;55:1484-1491.
a. For monitoring patients with GTD.
b. In conjunction with AFP, for determining prognosis and monitoring
patients with NSGCT of testis, ovary and other sites.
Diagnostic aid for trophoblastic disease. Serum hCG levels do not usually
differentiate between trophoblastic tumours and normal pregnancy.
However, very high levels outside the range for twin pregnancies may lead to
suspicion of a trophoblastic tumour. For diagnosing trophoblastic tumours,
hCG assays are usually used in combination with ultrasound.
14 Guidelines for the use of tumour markers Human Chorionic Gonadotropin (hCG) 15
Prostate Specific Antigen (PSA)
Structure Other potential uses
A 28.4 kDa single chain chymotrypsin-like serine protease containing 237 The value of PSA in screening for prostate cancer is controversial.
amino acids and a member of the glandular kallikrein family. Preliminary results from two randomized prospective trials were recently
published. One trial found no significant reduction in mortality from
Forms in serum prostate cancer, while the other found a 20% reduction in mortality, but at
Various molecular forms because of complex formation with protease the expense of overdiagnosis.
inhibitors. Major immunoreactive form is PSA complexed with
a1-antichymotrypsin (PSA-ACT). Other complexes occur such as PSA Reference range:
linked to a1-antitrypsin (trace quantity) and a2-macroglobulin (undetectable 0 - 4 µg/L (most frequently used) but some advocate age-related reference
by current immunoassays). A non-complexed free form (fPSA) represents 5 ranges as follows:
to 40% of the “total” PSA ( fPSA + a1-antichymotrypsin complex).
Age PSA
Physiological function Range µg/L
Partially responsible for the liquefaction of semen to promote the release and 40 - 49 0 - 2.5
motility of spermatozoa.
50 - 59 0 - 3.5
Malignancy with elevated levels 60 - 69 0 - 4.5
Present data suggests that prostate cancer is the only malignancy giving rise
to elevated PSA levels in serum. However, PSA has been found in cells from 70 - 79 0 - 6.5
various cancer types and different normal tissues. PSA is thus not completely Half life in serum
prostate specific. Approximately 2.5 days after radical prostatectomy. Half life after
radiotherapy may be many months.
Benign conditions with elevated levels
Benign prostatic hypertrophy (BPH), acute and chronic prostatitis, UTI, Effects of urological manipulations on PSA levels.
urinary retention. It is advisable to take blood for PSA measurement before rather than after
A number of urological manipulations such as TURP, prostate biopsy, any of these manipulations.
prostate massage and ejaculation may give rise to transient elevated levels. DRE May cause minor increases which are rarely of clinical
See Section Effects of Urological Manipulations on PSA Levels on the next significance.
page.
Prostate massage May cause minor elevations in some patients.
Physiological conditions with elevated levels Ejaculation Results conflicting but may increase PSA levels.
None described. TURP Increases PSA levels significantly. It is recommended to
Main clinical applications wait at least 6 weeks before drawing blood for PSA assay.
a. In combination with digital rectal examination PSA can aid the Needle Biopsy As with TURP, increases PSA levels significantly. Wait at
diagnosis of prostate cancer. least 6 weeks before drawing blood for PSA assay.
b. Determining prognosis in patients with prostate cancer. Ultrasound Increases PSA levels in a minority of subjects.
c. Surveillance following diagnosis of prostate cancer Cystoscopy Flexible cystoscopy does not appear to increase PSA levels
but rigid cystoscopy may increase levels.
d. Monitoring therapy in patients with diagnosed prostate cancer.
16 Guidelines for the use of tumour markers Prostate Specific Antigen (PSA) 17
Effect of drugs on PSA levels References

Finasteride and Dutasteride, 5-alpha-reductase inhibitors used to treat BPH, 1. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the
reduce PSA levels by approx. 50%. validation of the most commonly used cancer biomarker.
Cancer 2004;10:894-904.
Comment about assay
PSA assays should detect the free and complexed forms on an equimolar 2. Han M et al. Prostate-specific antigen and screening for prostate
basis. Furthermore, the assay should be standardised against the First cancer.
International Standard for PSA. Med Clinic N Am 2004;88:245-265.
Total PSA is stable for at least 6 hours at room temperature in uncentrifuged 3. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of
clotted blood. Five cycles of freezing and thawing caused no significant Clinical Biochemistry laboratory medicine practice guidelines for use
change. of tumor markers in testicular, prostate, colorectal, breast, and ovarian
cancers.
Clin Chem 2008;54:e11-79.
4. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church
TR, et al. Mortality results from a randomized prostate-cancer
screening trial.
N Engl J Med 2009;360:1310-1319.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen
V, et al. Screening and prostate-cancer mortality in a randomized
European study.
N Engl J Med 2009;360:1320-1328.
6. Barry, MJ. Screening for Prostate Cancer - The controversy that
refuses to die (editorial).
N Engl J Med 2009;360:1351-1354.
18 Guidelines for the use of tumour markers Prostate Specific Antigen (PSA) 19
Free PSA (fPSA)
Form in serum Comment about assay
As stated above, PSA exists in serum in both a bound and free form. The When using %fPSA, both the free and total PSA assay should be obtained
free form includes enzymically inactive pre-PSA, pro-PSA, clipped-PSA and from the same supplier. fPSA is less stable than total PSA, for medium and
the enzymatically active form of free PSA. The lower the %fPSA, the higher long-term storage, freezing at –70oC is recommended. Assay of complex
the probability of prostate cancer. PSA, i.e. PSA bound to ACT, appears to give similar information to the free/
total ratio in men with PSA levels between 2 and 10 µg/L.
To enhance the specificity of total PSA in detecting prostate cancer, Effect of urological manipulations on fPSA
especially when total PSA values are between 4 and 10 µg/L. The use of free/ All the manipulations which increase total PSA levels also increase the level
total PSA in men with PSA levels can reduce the number of unnecessary of free PSA as well as the percentage free.
biopsies.
Effect of drugs
Type of sample for assay While certain 5-alpha-reductase inhibitors, such as Finasteride and
Serum or plasma, assay should be carried out on same sample which had Dutasteride, reduce both total and free PSA levels, they do not significantly
total PSA determined. change the %fPSA level.
Reference range
fPSA results can be used in 2 ways: References
1. Chan DW et al. Analytical and clinical performance of Hybritech’s
1. Use of a single cut-off point. In a large prospective multi-centre
Tandem-R free PSA assay during a large multi-center clinical trial to
study with a cut off point of <25% fPSA (Ref 1), it was shown
determine the clinical utility of percentage of free PSA.
that unnecessary needle biopsies could be reduced by 20% while
Clin Chem 1999;45:1863-5.
maintaining a 95% cancer detection rate with total PSA levels
between 4 and 10 µg/L. 2. Woodrum DL et al. Interpretation of free PSA clinical research
studies for the detection of prostate cancer.
2. Probability of cancer: In the same multi-centre study, the following J Urol 1998;159:5-12.
relationships were found between % fPSA and probability of prostate
3. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price C, et
cancer.
al. Use of prostate-specific antigen (PSA) isoforms for the detection
% fPSA % Cancer of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic
Probability review and meta-analysis.
0-10 56 Eur Urol, 2005;48:386-99.
10-15 28
15-20 20
20-25 16
>25 8
20 Guidelines for the use of tumour markers Free PSA (fPSA) 21

Use of Serum Markers in Diagnosing
Cancer of Unknown Primary Origin
(Occult Cancers)
Cancers of unknown primary
Cancers of unknown primary origin or occult cancers are defined as
histologically proven malignant metastatic tumours whose primary origin
cannot be identified during pretreatment evaluation.
Overview of clinical utility
In general, serum markers are of little value in identifying the primary site.
This is because, with a small number of exceptions, currently available serum
markers are not organ-specific. Indeed, most of the available markers such
as CEA, CA 125, CA 19-9 and CA 15-3 can be elevated in most types of
advanced adenocarcinomas.
Markers that are potentially useful in diagnosing or excluding a likely site
are:
• PSA in men for including or excluding prostate cancer.
• AFP and hCG for including or excluding a germ cell tumour.
• Thyroglobulin for including or excluding a differentiated thyroid
tumour.
Reference
1. Sturgeon CM, Lai LC, Duffy MJ. Serum tumor markers: how to order
and interpret them.
Br Med J 2009;339:852-858.
22 Guidelines for the use of tumour markers Use of Serum Markers in Diagnosing Cancer of Unknown Primary Origin (Occult Cancers) 23
Tissue Markers in Breast Cancer
Estrogen and Progesterone Receptors (ER and PR) HER-2 (c-ErbB-2)
Clinical uses Clinical uses
a. For predicting response to hormone therapy in patients with either a. Mandatory uses: For the identification of patients who may be treated
early or advanced breast cancer. with trastuzumab (Herceptin) in the metastatic setting, and to identify
b. In combination with other factors, ER and PR may be used to patients that may be eligible for clinical trials of trastuzumab in the
determine prognosis. adjuvant setting.
Recommended assay b. In combination with other factors, HER-2 may also be used to
Immunohistochemistry with a validated antibody. determine prognosis.
c. Insufficient data is currently available to recommend HER-2 for
predicting response to endocrine therapy or any type of chemotherapy.
References Recommended assay
1. Duffy MJ. Biochemical markers in breast cancer: which ones are a. FISH or immunohistochemistry with validated antibodies and
clinically useful. standardized methodology. For equivocal cases (i.e., those with scores of
Clin Biochem 2001;34:347-352. 2+), testing with FISH should be carried out.
2. Duffy MJ. Predictive markers in breast and other cancers. b. The extracellular domain of HER-2 can be measured in serum.
Clin Chem 2005;51:494-503 Serum HER-2 levels may be used for post-operative surveillance and
3. Hammond MEH, Hayes DF, et al. American Society of Clinical monitoring therapy in patients with breast cancer. Based on evidence
Oncology-College of American Pathologists Guideline presently available, use of serum HER-2 has no advantage over CA
Recommendations for Immunohistochemical Testing of Estrogen 15-3. It may however, be of use if CA 15-3 is not elevated. Preliminary
and Progesterone Receptors in Breast Cancer. findings suggest that serum HER-2 may be of value in monitoring
J Clin Oncol 2010;28:2784-2795. Herceptin therapy.
References
1. Duffy MJ. Biochemical markers in breast cancer: which ones are
clinically useful.
Clin Biochem 2001;34:347-352.
2. Duffy MJ. Predictive markers in breast and other cancers.
Clin Chem 2005;51:494-503.
3. Wolff AC, Hammond MEH, et al. American Society of Clinical
Oncology-College of American Pathologists Guideline
Recommendations for Human Epidermal Growth Factor Receptor 2
Testing in Breast Cancer.
J Clin Oncol 2007;25:118-145
24 Guidelines for the use of tumour markers Tissue Markers in Breast Cancer 25
Urokinase Plasminogen Activator (uPA) and PAI-1

Clinical uses
a. Assay of uPA and PAI-1 can be carried out to identify lymph node-
negative breast cancer patients that may not need, or who are unlikely to
benefit from, adjuvant chemotherapy.
b. The prognostic value of these factors for lymph node-negative breast
cancer patients has been validated using both a randomised trial and a
pooled analysis.
Recommended assay
A validated ELISA
References
1. Duffy MJ. Urokinase plasminogen activator and its inhibitor PAI-1,
as prognostic markers in breast cancer: from pilot to level 1 evidence
studies.
Clin Chem 2002;48:1194-1197.
2. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Sweep F, et
al. For the German Chemo No Study Group. Randomized adjuvant
chemotherapy trial in high-risk node-negative breast cancer patients
identified by urokinase-type plasminogen activator and plasminogen
activator inhibitor type 1.
J Natl Cancer Instit 2001;93:913-920
3. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of
prognostic impact of tumor biological factors uPA and PAI-1 in 8377
breast cancer patients.
J Natl Cancer Instit 2002;94:116-128.
26 Guidelines for the use of tumour markers Tissue Markers in Breast Cancer 27
ACBI
Scientific
Committee
Guidelines

Guideline Tumour Markets 4th

Uploaded by

Copyright:

Available Formats

Guideline Tumour Markets 4th

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Guideline Tumour Markets 4th

Uploaded by

Copyright:

Available Formats

Guidelines for the use

Guidelines for the use of

Association of Clinical Biochemists in Ireland

Fourth edition: October 2010 Fourth edition: October 2010

Human Chorionic Gonadotropin (hCG) 14

Prostate Specific Antigen (PSA) 16

Free PSA (fPSA) 20

Use of Serum Markers in Diagnosing Cancer of

vi Guidelines for the use of tumour markers vii

viii Guidelines for the use of tumour markers ﻿ 1

2 Guidelines for the use of tumour markers ﻿ 3

4 Guidelines for the use of tumour markers Alpha-Fetoprotein (AFP) 5

6 Guidelines for the use of tumour markers CA 125 7

8 Guidelines for the use of tumour markers CA 15-3 9

10 Guidelines for the use of tumour markers CA 19-9 11

12 Guidelines for the use of tumour markers CEA 13

Effect of drugs on PSA levels References

20 Guidelines for the use of tumour markers Free PSA (fPSA) 21

Urokinase Plasminogen Activator (uPA) and PAI-1

You might also like

viii Guidelines for the use of tumour markers 1

2 Guidelines for the use of tumour markers 3